- Home
- EWTX
as 02-21-2025 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Edgewise Therapeutics Inc. EWTX prepares to release earnings report on 28 Feb 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 2.7B | IPO Year: | 2021 |
| Target Price: | $42.71 | AVG Volume (30 days): | 950.6K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.90 - $38.12 | Next Earning Date: | 02-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KOCH KEVIN | EWTX | President and CEO | Feb 5 '25 | Sell | $30.58 | 9,536 | $287,315.62 | 14,478 | |
| Derakhshan Behrad | EWTX | Chief Business Officer | Feb 5 '25 | Sell | $30.03 | 10,000 | $300,300.00 | 16,837 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Feb 5 '25 | Sell | $30.07 | 9,215 | $276,776.12 | 14,863 | |
| Donovan Joanne M. | EWTX | CMO | Jan 28 '25 | Sell | $27.63 | 25,000 | $690,657.50 | 16,358 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Dec 30 '24 | Sell | $27.37 | 100,000 | $2,737,470.00 | 14,863 | |
| Semigran Marc | EWTX | Chief Development Officer | Dec 24 '24 | Sell | $29.87 | 29,709 | $881,915.22 | 8,445 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Should You Invest in Edgewise Therapeutics (EWTX)?
MT Newswires
15 days ago
Edgewise Therapeutics Insider Sold Shares Worth $300,300, According to a Recent SEC Filing
MT Newswires
15 days ago
Edgewise Therapeutics Insider Sold Shares Worth $287,316, According to a Recent SEC Filing
MT Newswires
15 days ago
Edgewise Therapeutics Insider Sold Shares Worth $276,776, According to a Recent SEC Filing
Insider Monkey
a month ago
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?
MT Newswires
a month ago
Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall
Business Wire
a month ago
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
MT Newswires
a month ago
Stifel Nicolaus Initiates Coverage on Edgewise Therapeutics With Hold Rating, $30 Price Target
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.